OMO-103 is under clinical development by Peptomyc and currently in Phase I for Osteosarcoma. According to GlobalData, Phase I drugs for Osteosarcoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OMO-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OMO-103 overview
OMO-103 is under development for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC), advanced high-grade osteosarcoma and metastatic pancreatic cancer. The therapeutic candidate is a cell penetrating peptide (CPP) and administered through intravenous route. It acts by targeting Myc proto-oncogene protein.
It was under development for treatment of solid tumors including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), sarcoma, salivary gland cancer, pancreatic cancer and colorectal cancer (CRC).
Peptomyc overview
Peptomyc is a drug development company focusing on the development of cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. The company offers a foundational treatment to any cancer patient with abnormal MYC activity. It uses mini-protein therapeutics to directly inhibit MYC which is the central engine for cancer proliferation, survival, and resistance to treatment. The company offers OMO-103, a MYC inhibitor which targets pancreatic ductal adenocarcinoma. Peptomyc is headquartered in Barcelona, Spain.
For a complete picture of OMO-103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
